Since few years, there is an increasing penetration of Mass Spectrometry techniques in the Clinical field. MALDI-TOF technology has widely invested microbiological laboratories and LC-MS/MS is replacing many immunoassays tests in clinical chemistry thanks to better precision for quantitation, possibilities of multiplexing tests and the less cross-contamination inherent to Immunoassays tests. Shimadzu is a major player in that revolution and we strive to ease that penetration of Mass Spectrometry by developping new solutions to increase patient outcome.
Development of a Forensic Toxicology Database for screening of DOA on a LCMS tandem
Prof. Franck SAINT-MARCOUX
Department of Pharmacology and Toxicology, University Hospital of Limoges, France
"Through the European Innovation Center Shimadzu is the first company who proposes us an actual and effective collaboration. This is a win-win and exciting partnership."
Development of a Forensic toxicology database with 1280 compounds for LC-MS/MS. The project, started in 2017, has been realized and achieved by the Dr Tiphaine ROBIN who sustained her Ph.D. on 11/12/2020. Her work has been released as a product to serve the European and Worldwide market: https://www.shimadzu.eu/forensic-toxicology-database
See publication for more info
Development of a Forensic toxicology database with 1280 compounds for High Resolution LCMS with the addition of NPS (Novel Psychoactive Substances) and their metabolites. The project is conducted by the Ph.D. student Elies ZARROUK.
HCC cancer detection with probe electrospray ionization mass spectrometry (PESI-MS)
"For a researcher, having a prototype and the first to try something is a desire your whole life. The instrument is brand new. The approach is brand new. It was a very good opportunity."
Prof. Enrico DAVOLI
Mario Negri Institute for Pharmacological Research Milano, Italy
"Be part of the EUIC Shimadzu is a fantastic opportunity to develop clinical proteomics using last generation and high-level mass spectrometer. Within this long-term partnership, we will be able to strengthen our clinical innovations, acquire additional technical expertise and explore new clinical markets for Shimadzu."
Development of a multiplex and targeted mass spectrometry for synucleins quantification in biological samples (CSF, plasma, saliva) in the context of neurodegenerative diseases. The project is conducted by the Ph.D. student Marie-Laure PONS.
Joint study concerning the Mass spectrometry-based blood amyloid-beta Analysis, opening the door to new advancements in Research.
Biobank sample quality control with probe electrospray ionization mass spectrometry (PESI-MS)
"For CBmed the European Innovation Center of Shimadzu is an important partner on our way to identify new biomarkers in the field of medicine by providing an insight into the latest technology and extensive knowledge about metabolomics."
Dr. Barbara PRIETL
CBMED Center for Biomarker Research in Medicine Graz, Austria
"The CLAM-2000 is the first system that allows to have procedures where no human intervention is necessary when the primary tube is loaded on board the system."
Development of a fully automated solution based on LC-MS/MS for toxicology screening and quantitation. The project has been fullfiled by the Dr Tiphaine ROBIN who sustained her Ph.D. on 11/12/2020. Her work is based on the use of the automated sample preparation system CLAM-2030 and a tandem LCMS model LCMS-8060.